Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Open-label, Randomized, Two-arm Study, to Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients With EGFR Mutated NSCLC and Asymptomatic Brain Metastases.

NCT05033691 is registered in ClinicalTrials.gov with Hadassah Medical Organization as lead sponsor.

NCT NCT05033691
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05033691 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Open-label, Randomized, Two-arm Study, to Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients With EGFR Mutated NSCLC and Asymptomatic Brain Metastases.
Lead sponsor
Hadassah Medical Organization
Phase
Not applicable
Overall status
Recruiting
Start date
March 9, 2021
Completion date
December 31, 2026
Enrollment
162 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brain metastases, egf-r positive non-small cell lung cancer, egfr gene mutation, non-small cell lung cancer, nsclc